Evommune, Inc. (EVMN)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$6.37+5.46%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · EVMN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.7% |
| Our one-year growth estimate | diamond | -97.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 27.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
EVMN — private placement
Dated 2026-11-04
Entry into a Material Definitive Agreement. Hinova Pharmaceuticals Inc. License Transaction License Agreement On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Hinova Pharmaceuticals Inc., a company incorporated in the People’s Republic of China (“Hinova”). Pursuant to the License Agreement and subject to certain rights retained by Hinova, Hinova granted the Company the exclusive and sublicensable rights to develop,…
Why it matters: EVO756 failed its AD and CSU trials. The migraine study is its remaining named test.
Watch forThe roughly 330-person trial reports 2027 results, with fewer monthly migraine days than placebo.
Also watch forThe trial misses its main goal of reducing monthly migraine days versus placebo, or results slip past 2027.
Why it matters: The full results can show how strong the earlier AD signal was. They may guide the planned Phase 2b trial.
Watch forThe full data show clear gains on key secondary measures and changes in both Th2 and non-Th2 markers.
Also watch forThe full data show no clear gains on key secondary measures or no change in the named markers.
Why it matters: EVO301 is now the lead AD program after EVO756 failed in AD. A trial start would mark its next major step.
Supportive ifThe company starts the planned EVO301 AD Phase 2b trial by mid-2027 with at least three dose plans.
Worry ifThe trial has not started by mid-2027, or the company reports a delay tied to scale-up or safety tests.
Why it matters: Evommune has no product revenue and reported a $32.2 million loss in Q2. Cash helps fund its planned trials.
Worry ifCash and investments stay near or above $288 million, and management keeps its runway view through 2028.
Less concerning ifCash and investments fall sharply from $288 million, or management shortens its runway view from 2028.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$253 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $1,127 loss on $10,000 · 11.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,385 loss on $10,000 · 83.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The update can show whether EVO301 planning and EVO756 migraine work stay on schedule.
Watch forThe December 10 update keeps the EVO301 trial start at mid-2027 and migraine results in 2027.
Also watch forThe update pushes either milestone beyond the stated timing or reports a trial pause.